reports
Moody's Ratings withdraws CSI Compressco's ratings following debt exti...
Moody's Ratings (Moody's) withdrew all of CSI Compressco LP's (Compressco) ratings, including its Caa1 Corporate Family Rating (CFR), Caa1-PD Probability of Default Rating (PDR), and SGL-3 Speculative Grade Liquidity Rating (SGL). The outlook was changed to rating withdrawn from rating under review....
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, May 10, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 48,150 shares of the Company’s common stock to four new employees (the “Inducement Gra...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANN ARBOR, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 8, 2024, the Company granted 16 new employees 62,300 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual...
Optinose Announces Reporting Date for First Quarter 2024 Financial Res...
Optinose Announces Reporting Date for First Quarter 2024 Financial Results Conference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern Time YARDLEY, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2024 and corporate updates, before market open, on Tuesday, May 14, 2024. Company to Host Conference CallMembers of the Company’s leadership team will host a conference call to discuss f...
NHC Reports First Quarter 2024 Earnings
MURFREESBORO, Tenn.--(BUSINESS WIRE)-- (NYSE American: ), the nation's oldest publicly traded senior health care company, announced today net operating revenues for the quarter ended March 31, 2024 totaled $297,176,000 compared to $269,563,000 for the quarter ended March 31, 2023, an increase of 10.2%. For the quarter ended March 31, 2024, the reported GAAP net income attributable to NHC was $26,213,000 compared to $11,723,000 for the same period in 2023. Excluding the unrealized gains in our marketable equity securities portfolio and other non-GAAP adjustments, adjusted net income for the ...
NHC Announces 3.4% Increase in Common Dividend
MURFREESBORO, Tenn.--(BUSINESS WIRE)-- (NYSE American: NHC), the nation’s oldest publicly traded long-term health care company, announced today that it will pay a quarterly dividend of 61 cents per common share to shareholders of record on June 28, 2024 and payable on August 1, 2024. This represents a 3.4% increase over last quarter’s regular common dividend. Forward-Looking Statements Statements in this press release that are not historical facts are forward-looking statements. NHC cautions investors that any forward-looking statements made involve risks and uncertainties and are not gua...
89bio Reports First Quarter 2024 Financial Results and Provides Corpor...
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update –Initiated Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic (F2-F3) metabolic dysfunction-associated steatohepatitis (MASH) patients– –Expect to initiate ENLIGHTEN-Cirrhosis trial this quarter in MASH patients with compensated cirrhosis (F4)– –Granted Priority Medicines (PRIME) status from the European Medicines Agency (EMA) for pegozafermin in the treatment of MASH with fibrosis and compensated cirrhosis– –Data from the 48-Week Extension Phase of the ENLIVEN Phase 2b Trial to ...
Quest Resource Holding Corporation Reports First Quarter 2024 Financia...
Quest Resource Holding Corporation Reports First Quarter 2024 Financial Results Double-Digit Growth in Gross Profit Resulting from Business Expansion and Efficiency Gains Significant New Business Wins and Pipeline Growth Reflect Company’s Strong Value Proposition and Momentum Investor Conference Call & Webcast to be held at 5pm ET on Thursday, May 9, 2024 THE COLONY, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Quest Resource Holding Corporation (NASDAQ: QRHC) (“Quest”), a national leader in environmental waste and recycling services, today announced financial results for the first quarter ...
Optinose Announces $55 Million Registered Direct Offering
Optinose Announces $55 Million Registered Direct Offering Led by Nantahala Capital and The D. E. Shaw Group with participation from existing and new investors Post-offering cash balance of ~$100 million expected to fund operating plan through 2025 Company expects XHANCE net revenues to be between $85 to $95 million for full year 2024 YARDLEY, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it has entered into agreements for the sale of a...
89bio to Participate in the BofA Securities 2024 Health Care Conferenc...
89bio to Participate in the BofA Securities 2024 Health Care Conference SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will present at the BofA Securites 2024 Health Care Conference on Wednesday, May 15, 2024 at 2:20 PM PDT and participate in one-on-one investor meetings. The webcast of the presentation will be accessible and in the investor s...
Clene Reports First Quarter 2024 Financial Results and Recent Operatin...
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights Data from long-term extension of Phase 2 VISIONARY-MS clinical trial of CNM-Au8® demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p
Cartesian Therapeutics Reports First Quarter 2024 Financial Results an...
Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Topline data from Phase 2b trial of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis on track for mid-2024 On track to dose first patient in Phase 2 trial of Descartes-08 in SLE in 2Q24, as well as Phase 2 basket studies in additional autoimmune indications in 2H24 New headquarters expected to support scale of wholly owned, in-house cGMP manufacturing capabilities for clinical and commercial supply of Com...
- Jay Kornreich
- Richard Anderson
- Sydnie Rohme
OPKO Health Reports First Quarter 2024 Business Highlights and Financi...
OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024. First quarter business highlights include the following: Entered into an agreement with Labcorp to sell select assets of BioReference Health. The transaction includes the sale of BioReference Health’s laboratory testing businesses focused on clinical diagnostics and women’s health, excludi...
Esperion Reports First Quarter 2024 Financial Results
Esperion Reports First Quarter 2024 Financial Results – Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – – Q1 Retail Prescription Equivalents Grew 43% Y/Y and 6% Q/Q, Increased Momentum from Label Expansions Expected Throughout 2024 – – Received U.S. FDA Approval of Broad New Label Expansions for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet, Becoming the First LDL-C Lowering Non-Statins to Prevent Heart Attacks and Reduce Cardiovascular Risk in Prima...
Coty and Lena Gercke Embark on New License Agreement
NEW YORK--(BUSINESS WIRE)-- Today, Coty Inc. (NYSE:COTY) (Paris:COTY), one of the world’s largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, skin and body care, is pleased to announce that it has signed a long term license agreement with Lena Gercke to develop, produce, and distribute LeGer’s debut fragrance. This agreement marks the beginning of a long-term partnership between Coty and German Television Presenter and Model, Lena Gercke. The agreement is rooted in a mutual focus on empowerment, inspiration, and innovation. The collaboration comes as...
Hawthorn Bancshares Inc: 1 director
A director at Hawthorn Bancshares Inc bought 15,000 shares at 19.626USD and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
- Jonathan Moreland
SAIA SAIA INC.
RYI RYERSON HOLDING CORPORATION
LTRX LANTRONIX INC.
HXL HEXCEL CORPORATION
HOO HERBALIFE NUTRITION LTD.
AIN ALBANY INTERNATIONAL CORP. CLASS A
HWBK HAWTHORN BANCSHARES
HI HILLENBRAND INC.
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
EAF GRAFTECH INTERNATIONAL
GH GUARDANT HEALTH
DNA GINKGO BIOWORKS HOLDINGS
TBBK INC.
RXO_w THE BANCORP
VSTS_w INC.
CFFI RXO INC
RENT VESTIS CORPORATION
C&F FINANCIAL CORPORATION
RENT THE RUNWAY INC
Coty Reports Strong Results Ahead of Beauty Market, with Double-Digit ...
NEW YORK--(BUSINESS WIRE)-- Coty Inc. (NYSE: COTY) (Paris:COTY) ("Coty" or "the Company") today announced its results for the third quarter of fiscal year 2024, ended March 31, 2024. The Company's strong above-market sales growth, reported and adjusted operating income growth, and reported and adjusted gross and operating margin expansion in Q3 solidifies nearly four years of Coty reporting results in-line to ahead of expectations. In 3Q24, Coty's net revenues grew 8% on a reported basis and 10% on a LFL basis, with reported and LFL results supported by growth in fragrances, color cosmetics,...
- Jonathan Moreland
RF REGIONS FINANCIAL CORPORATION
NEOG NEOGEN CORPORATION
LGND LIGAND PHARMACEUTICALS INCORPORATED
INTC INTEL CORPORATION
HXL HEXCEL CORPORATION
FFIN FIRST FINANCIAL BANKSHARES INC
EGBN EAGLE BANCORP INC.
DLTR DOLLAR TREE INC.
CINF CINCINNATI FINANCIAL CORPORATION
CHDN CHURCHILL DOWNS INCORPORATED
SWKS SKYWORKS SOLUTIONS INC.
HTLD HEARTLAND EXPRESS INC.
ZUMZ ZUMIEZ INC.
TRT TRIO TECH INTERNATIONAL
CET CENTRAL SECURITIES CORP.
LIND LINDBLAD EXPEDITIONS HOLDINGS
WDFC WD-40 COMPANY
FEIM FREQUENCY ELECTRONICS INC.
AINC ASHFORD
CLF CLIFFS NATURAL RESOURCES INC.
PWOD PENNS WOODS BANCORP INC.
ATOM ATOMERA
LOVE LOVESAC
FVCB FVCBANKCORP
INMB INMUNE BIO
MCFT INC.
CAPR MASTERCRAFT BOAT HOLDINGS
RYES CAPRICOR THERAPEUTICS
HQL PATRIOT MINEFINDERS INC.
SOWG TEKLA LIFE SCIENCES INVESTORS
CPZ SOW GOOD INC.
AUID CALAMOS LONG/SHORT EQUITY AND DYNAMIC INCOME TRUST
JBHT IPSIDY INC.
TBBK J.B. HUNT TRANSPORT SERVICES
MPA INC.
FTHY THE BANCORP
AIKI INC.
BHVN BLACKROCK MUNIYIELD PENNSYLVANIA FD
BUKS FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND
ACRV AIKIDO PHARMA INC.
ZURA BIOHAVEN LTD
ABEO BUTLER NATIONAL CORP
STCN ACRIVON THERAPEUTICS INC
KRRO ZURA BIO LTD
LSXMA ABEONA THERAPEUTICS INC.
EP STEEL CONNECT INC
INTZ KORRO BIO INC
LGVN LIBERTY SIRIUSXM GROUP
OCX EMPIRE PETROLEUM CORP
EYPT INTRUSION INC
IZEA LONGEVERON INC
CFFI ONCOCYTE CORPORATION
EYEPOINT PHARMACEUTICALS
INC.
IZEA WORLDWIDE INC
C&F FINANCIAL CORPORATION
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.